BCTX May 2024 2.500 put
| Previous Close | 0.6500 |
| Open | 0.6500 |
| Bid | 0.9000 |
| Ask | 1.3500 |
| Strike | 2.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.6500 - 0.6500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 4 |
GlobeNewswireBriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,9
- GlobeNewswire
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common share
- GlobeNewswire
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca
